Memantine Accord (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium influx that can cause neuronal injury. By moderating glutamate‑mediated excitotoxicity, it helps protect brain cells and supports more stable neural signaling in patients with Alzheimer’s disease.

The dosing regimen for Memantine Accord is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Healthcare professionals set the appropriate dose and titration schedule for each individual.

The safety of memantine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Memantine Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas drugs such as donepezil are acetylcholinesterase inhibitors. Memantine targets excitotoxic pathways, while acetylcholinesterase inhibitors enhance cholinergic transmission. Clinical choice depends on disease stage, patient tolerance, and physician assessment.

Memantine Accord tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability.

Memantine Accord is taken orally, usually with water. The tablet is swallowed whole and can be taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious adverse events include seizures, severe allergic reactions such as anaphylaxis, hallucinations, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience any of these symptoms while on therapy.

Memantine Accord is contraindicated in individuals with known hypersensitivity to memantine or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled epilepsy, or those taking interacting NMDA agonists.